On September 17, 2020 OncoHost, a global leader in host response profiling for improved personalized cancer therapy, announced today that its research on the use of its plasma proteomics platform using advanced bioinformatic analysis to improve outcomes of immunotherapy-treated non-small cell lung cancer (NSCLC) patients will be presented at the ESMO (Free ESMO Whitepaper) Virtual Congress 2020 (Press release, OncoHost, SEP 17, 2020, View Source [SID1234565327]). The clinical study was conducted in collaboration with the Technion Institute of Technology, the Chaim Sheba Medical Center Institute of Oncology, Thomas Jefferson University and the University of Connecticut. The study focuses on how through analyzing individual host response profiles (i.e. the patient’s reaction), oncologists may be able to harness said host response to better predict clinical outcomes and suggest optimal combination treatment with immunotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Immunotherapy based on immune checkpoint inhibitors (ICIs) has made a paradigm shift in oncology, unfortunately, not every patient has the same response to this exciting treatment modality," said Professor Adam Dicker, Sr. VP and Chair & Professor of Radiation Oncology, Pharmacology & Experimental Therapeutics at Jefferson University and chief medical officer at OncoHost. "Our study characterizes the host response to ICI, aiding in the discovery of predictive biomarkers for the potential for clinical benefit in NSCLC. This represents an important step for predicting host response in blood-based proteomic biomarkers – precision oncology at its best."

The study, conducted on OncoHost’s machine learning-based Host Response Profiling platform, PROphet, demonstrated that analyzing host response profiles in patients aids in the discovery of predictive biomarkers for patient stratification in NSCLC, and that the mechanisms of resistance to immunotherapy are associated with host response to the drug. The research also revealed that the advanced bioinformatic analysis and host response identification, characterization and analysis based on proteomic data can help predict patient outcomes with high accuracy.

"This research demonstrates the value of our first of-its-kind profiling platform, which provides a new layer of information, enabling early identification of non-responsiveness to cancer treatments and discovery of new targets to overcome treatment resistance," said Dr. Ofer Sharon, CEO of OncoHost. "Using this platform in clinical settings can help physicians better predict response for NSCLC patients and identify previously unanticipated targets for future interventions and clinical trials."

The ESMO (Free ESMO Whitepaper) Virtual Congress 2020 is taking place September 19-21.

Poster Title: Blood-based proteomic biomarkers for predicting response to immunotherapy in non-small cell lung cancer.
Abstract #: 3213
Presentation #: 1314P

The poster will be available on the ESMO (Free ESMO Whitepaper) website.